89151-45-1

Basic information

• Product Name: 1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE
• Synonyms: 1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE;N-TERT-BUTOXYCARBONYL-4-[2-(4-TOLUENESULFONYLOXY)ETHYL] PIPERIDINE;N-tert-Butoxycarbonyl-4-[2-(4-toluenesulfonyloxy)ethyl]piperidine95%;N-tert-Butoxycarbonyl-4-[2-(4-toluenesulfonyloxy)ethyl];N-Boc-4-[2-(4-toluenesulfonyloxy)ethyl]piperidine;Zinc02563762
• CAS NO: 89151-45-1
• Molecular Formula: C₁₉H₂₉NO₅S
• Molecular Weight: 383.5
• Mol File: 89151-45-1.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 499.224°C at 760 mmHg
• Flash Point: 255.722°C
• Appearance: /
• Density: 1.158g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.523
• Storage Temp.: 2-8°C
• PKA: -1.53±0.40(Predicted)
• CAS DataBase Reference: 1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE(89151-45-1)
• EPA Substance Registry System: 1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE(89151-45-1)

Safety Data

• Hazardous Substances Data: 89151-45-1(Hazardous Substances Data)

Usage

General Description

1-BOC-4-[2-(toluene-4-sulfonyloxy)-ethyl]-piperidine is a chemical compound with the molecular formula C21H31NO4S. It is a piperidine derivative with a BOC (tert-butoxycarbonyl) protecting group at the nitrogen atom and a toluene-4-sulfonyloxy (Tos) group attached to the ethyl side chain. 1-BOC-4-[2-(TOLUENE-4-SULFONYLOXY)-ETHYL]-PIPERIDINE is commonly used as an intermediate in organic synthesis and in the pharmaceutical industry for the preparation of various drugs and bioactive molecules. It is important to handle and use this compound with caution and in accordance with safety regulations due to its potential hazards and risks associated with its handling and storage.

InChI:InChI=1/C19H29NO5S/c1-15-5-7-17(8-6-15)26(22,23)24-14-11-16-9-12-20(13-10-16)18(21)25-19(2,3)4/h5-8,16H,9-14H2,1-4H3

Upstream product

• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 98-59-9 p-toluenesulfonyl chloride 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 

Downstream Products

• 167143-59-1 1-t-butoxycarbonyl-4-(2-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}ethyl)piperidine 
• 142247-37-8 4-(3-ethoxycarbonyl-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 252918-94-8 1-(tert-butoxycarbonyl)-4-[2-phenoxyethyl]piperidine 
• 718610-53-8 N-tert-butoxycarbonyl-4-[2-(4-methylthiophenylthio)ethyl]piperidine 
• 833491-25-1 tert-butyl 4-[2-({1-[(benzyloxy)carbonyl]piperidin-4-yl}sulfonyl)ethyl]piperidine-1-carboxylate 
• 1092513-09-1 tert-butyl 4-{2-[(2-{[(3-methoxybenzyl)amino]carbonyl}-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)methoxy]ethyl}piperidine-1-carboxylate 
• 1146960-35-1 tert-butyl 4-[2-(2-tert-butylphenoxy)ethyl]piperidine-1-carboxylate 
• 1360625-60-0 4-[2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl]piperidine-1-carboxylic acid tert-butyl ester 
• 1360684-76-9 3-(4-{2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl}piperidine-1-sulfonyl)quinoline 
• 1360625-63-3 3-(4-{2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl}piperidine-1-sulfonyl)quinoline hydrochloride 
• 1360684-77-0 4-(4-{2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl}piperidine-1-sulfonyl)isoquinoline 
• 1360625-64-4 4-(4-{2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl}piperidine-1-sulfonyl)isoquinoline hydrochloride 
• 14759-09-2 1-(2-(piperidin-4-yl)ethyl)piperidine 
• 944411-92-1 4-(2-piperidin-1-ylethyl)piperidine-1-carboxylic acid (4-bromophenyl)amide 

Relevant articles and documents

BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

SMARCA DEGRADERS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/o

Biological Evaluation and X-ray Co-crystal Structures of Cyclohexylpyrrolidine Ligands for Trypanothione Reductase, an Enzyme from the Redox Metabolism of Trypanosoma

The tropical diseases human African trypanosomiasis, Chagas disease, and the various forms of leishmaniasis are caused by parasites of the family of trypanosomatids. These protozoa possess a unique redox metabolism based on trypanothione and trypanothione reductase (TR), making TR a promising drug target. We report the optimization of properties and potency of cyclohexylpyrrolidine inhibitors of TR by structure-based design. The best inhibitors were freely soluble and showed competitive inhibition constants (Ki) against Trypanosoma (T.) brucei TR and T. cruzi TR and in vitro activities (half-maximal inhibitory concentration, IC50) against these parasites in the low micromolar range, with high selectivity against human glutathione reductase. X-ray co-crystal structures confirmed the binding of the ligands to the hydrophobic wall of the “mepacrine binding site” with the new, solubility-providing vectors oriented toward the surface of the large active site.